Thesis title: An Investigation into Helical Asymmetry – Design, Synthesis and Evaluation of a Helicenoidal DMAP Analogue Nucleophilic Catalyst.
Overall grade average: 77%
A-Levels: Chemistry (A), Biology (A), Geography (A)
GCSEs: 9 GCSE passes at A* (5) and A (4) including Chemistry, Maths and English
Abnormal coordination of Arduengo's carbene upon reaction with M3(CO)12 (M = Ru, Os) Crittall, M. R; Ellul, C. E; Mahon, M. F; Saker, O; Whittlesey, M. K. Dalton Transactions, 2008, 32, 4209.
Design, Synthesis and Evaluation of a Helicenoidal DMAP Lewis Base Catalyst
Crittall, M. R; Rzepa, H. S.; Carbery, D. R. Org. Lett. 2011, 13, 1250.
Point-to-helical transfer for a scalable and resolution-free synthesis of a helicenoidal DMAP organocatalyst Crittall, M. R; Fairhurst, N. W. G; Carbery, D. R. Chem. Commun., 2012, 48, 11181.
In vitro and in vivo antifungal profile of a novel and long acting inhaled azole, PC945, on Aspergillus fumigatus infection
Kazuhiro Ito, Thomas Colley, Pete Strong, Garth Rapeport, Gurpreet Sehra, Lauren Anderson-Dring, John Murray, Alexandre Alanio, Steven Kelly, Diane Kelly, Andrew Warrilow, Josie Parker, Yasuo Kizawa, Genki Kimura, Takahiro Nakaoki, Mihiro Sunose, Stuart Onions, Damien Crepin, Franz Legasse, Matthew Crittall, Jonathan Shannon, Michael Crooke, John King-Underwood, and Stephane Bretagne. Submitted for publication to Antimicrobial Agents and Chemotherapy (2017)
I am responsible for providing integrated drug discovery services to a variety of clients. I have worked in a multitude of therapeutic areas – anti-fungal, anti-cancer, type II diabetes, anti-inflammatory. This has involved playing a key role in both the design and synthesis of novel medicines and the understanding of complex pharmacokinetic and pharmacological data to drive projects. In addition, I have contributed to the development and scale-up of novel anti-fungal medicines, one of which has now entered early-stage clinical trials. I have also been involved in numerous multi-gram scale-ups to support PK and animal studies for novel type II diabetes drug candidates – one of which has been nominated for phase I clinical trials
My time at Peakdale entalied taking responsibility for synthesising and delivering requested pharmaceutical targets to the customer (Pfizer). I was also a supervisor of a Microsoft Visual Basic operated high-throughput automated purification system and analytical chiral HPLC system.
My time as a placement student at GSK involved developing a generic extraction method to improve analysis of the metabolome of control animal tissues. Large quantities of complex multivariate data were interpreted using Principal Component Analysis (PCA).
Connect
Copyright 2017 Matthew R. Crittall